Needham Maintains Buy on Cormedix, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on Cormedix (NASDAQ:CRMD) and raises the price target from $10 to $18.
October 31, 2024 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reaffirmed a Buy rating on Cormedix and increased the price target from $10 to $18, indicating a positive outlook.
The increase in the price target from $10 to $18 by a reputable analyst suggests a strong positive outlook for Cormedix. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100